-
1
-
-
2242477091
-
Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk angioplasty
-
The EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk angioplasty. N Engl J Med 1994;330:956-961.
-
(1994)
N Engl J Med
, vol.330
, pp. 956-961
-
-
-
2
-
-
0034676781
-
Novel dosing regimen of epitifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
-
The ESPRIT Investigators. Novel dosing regimen of epitifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037-2044.
-
(2000)
Lancet
, vol.356
, pp. 2037-2044
-
-
-
3
-
-
1842369101
-
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
-
The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
-
(1997)
N Engl J Med
, vol.336
, pp. 1689-1696
-
-
-
4
-
-
0028943980
-
Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)
-
Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Am J Cardiol 1995;75:559-562.
-
(1995)
Am J Cardiol
, vol.75
, pp. 559-562
-
-
Moliterno, D.J.1
Califf, R.M.2
Aguirre, F.V.3
-
5
-
-
0031041549
-
In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time
-
Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997;95:614-617.
-
(1997)
Circulation
, vol.95
, pp. 614-617
-
-
Ammar, T.1
Scudder, L.E.2
Coller, B.S.3
-
6
-
-
0034125135
-
In vivo demonstration of an antithrombin effect of abciximab
-
Ambrose JA, Hawkey M, Badimon JJ, et al. In vivo demonstration of an antithrombin effect of abciximab. Am J Cardiol 2000;86:150-152.
-
(2000)
Am J Cardiol
, vol.86
, pp. 150-152
-
-
Ambrose, J.A.1
Hawkey, M.2
Badimon, J.J.3
-
7
-
-
0032508297
-
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
-
The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
-
(1998)
Lancet
, vol.352
, pp. 87-92
-
-
-
8
-
-
0032887497
-
Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors
-
Blankenship JC. Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors. Am Heart J 1999;138:287-296.
-
(1999)
Am Heart J
, vol.138
, pp. 287-296
-
-
Blankenship, J.C.1
-
9
-
-
7144261069
-
Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to minimize platelet aggregation and coronary thrombosis
-
Mandak JS, Blankenship JC, Gardner LH, et al. Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to minimize platelet aggregation and coronary thrombosis. J Am Coll Cardiol 1998;31:1518-1524.
-
(1998)
J Am Coll Cardiol
, vol.31
, pp. 1518-1524
-
-
Mandak, J.S.1
Blankenship, J.C.2
Gardner, L.H.3
-
10
-
-
0029914728
-
Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
-
Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996;98:863-874.
-
(1996)
J Clin Invest
, vol.98
, pp. 863-874
-
-
Reverter, J.C.1
Beguin, S.2
Kessels, H.3
Kumar, R.4
Hemker, H.C.5
Coller, B.S.6
-
11
-
-
0032526550
-
Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity
-
Pedicord DL, Thomas BE, Mousa SA, Dicker IB. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Thromb Res 1998;90:247-258.
-
(1998)
Thromb Res
, vol.90
, pp. 247-258
-
-
Pedicord, D.L.1
Thomas, B.E.2
Mousa, S.A.3
Dicker, I.B.4
-
12
-
-
0031757773
-
Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients
-
Keularts IM, Beguin S, de Zwaan C, Hemker HC. Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients. Thromb Haemost 1998;80:370-371.
-
(1998)
Thromb Haemost
, vol.80
, pp. 370-371
-
-
Keularts, I.M.1
Beguin, S.2
De Zwaan, C.3
Hemker, H.C.4
-
13
-
-
0027301820
-
Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect
-
Gemmell CH, Sefton MV, Yeo EL. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect. J Biol Chem 1993;268:14586-14589.
-
(1993)
J Biol Chem
, vol.268
, pp. 14586-14589
-
-
Gemmell, C.H.1
Sefton, M.V.2
Yeo, E.L.3
-
14
-
-
0033828457
-
GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood
-
Furman MI, Krueger LA, Frelinger AL, et al. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost 2000;84:492-498.
-
(2000)
Thromb Haemost
, vol.84
, pp. 492-498
-
-
Furman, M.I.1
Krueger, L.A.2
Frelinger, A.L.3
-
16
-
-
0032576475
-
Activation of alphaVbeta3 on vascular cells controls recognition of prothrombin
-
Byzova TV, Plow EF. Activation of alphaVbeta3 on vascular cells controls recognition of prothrombin. J Cell Biol 1998;143:2081-2092.
-
(1998)
J Cell Biol
, vol.143
, pp. 2081-2092
-
-
Byzova, T.V.1
Plow, E.F.2
-
17
-
-
0028261576
-
Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty
-
Avendano A, Ferguson JJ. Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:907-910.
-
(1994)
J Am Coll Cardiol
, vol.23
, pp. 907-910
-
-
Avendano, A.1
Ferguson, J.J.2
-
18
-
-
0028833085
-
Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty
-
Wilson JM, Dougherty KG, Ellis KO, Ferguson JJ. Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn 1995;34:1-5.
-
(1995)
Cathet Cardiovasc Diagn
, vol.34
, pp. 1-5
-
-
Wilson, J.M.1
Dougherty, K.G.2
Ellis, K.O.3
Ferguson, J.J.4
|